Upcoming event

Tags

[68Ga]Ga-DPI-4452 PET/CT, 3D reconstruction, adjuvant pembrolizumab, advanced RCC, Article of the Month, Artificial intelligence, ASCO GU22, ASCO21, AUA21, augmented reality, belzutifan, biomarkers, Cabozantinib, CAIN trial, Carcinoma, CARE1 trial, ccRCC, CheckMate-214, CheckMate-9ER, Checkpoint Inhibitor, Chronic kidney disease, clampless surgery, clear cell renal cell carcinoma, Cryosurgery, cystic masses, diagnostics, durvalumab, EAU, EAU21, EAU22, EMUC2026, EMUC21, EMUC22, enucleoresection, ERUS 2026, ERUS22, ESMO21, ESMO25, expert interview, first-line, first-line treatment, Frail patient​, Glomerular filtration rate, Guidelines, histology, histotripsy, imaging, IMDC risk model, immunotherapy, International Metastatic Renal Cell Carcinoma Database Consortium, intraoperative cyst rupture, intraoperative ultrasound, Kidney cancer, kidney-preserving, Laparoscopy, lenvatinib, localised renal cell carcinoma, Lymph node metastases, Lymph nodes, Metastasectomy, metastatic clear-cell renal cell carcinoma, metastatic disease, metastatic RCC, MK-1308A, Mortality, mRCC, neoadjuvant immunotherapy, Neoplasm metastasis, Neoplasm recurrence, Nephrectomy, Nephron-sparing surgery, Nivolumab, oligometastatic renal cell carcinoma, omRCC, Overall survival, papillary tumour, Partial nephrectomy, patient reported outcomes, PD-L1+, PE-PE trial, pembrolizumab, precision therapy, Prognostication, quality of life, Radical nephrectomy, Radical surgery, RAMPART trial, RCC, Renal cancer, Renal cell, Renal cell carcinoma, Renal Cell Carcinoma guidelines, Renal cryoablation, Renal function, Renal Transplantation, Renorrhaphy, resected renal cell carcinoma, risk stratification, robot-assisted partial nephrectomy, Robotic, robotic partial nephrectomy, Robotic prostatectomy, Robotic surgery, selective clamping, stereotactic body radiation therapy, Survival outcome, Suture, sutureless partial nephrectomy, Targeted therapies, TKIs, Treatment response, tumour enucleation, tumour genomics, tumour pseudocapsule rupture, tyrosine kinase inhibitors, Urological surgery, UROonco2025, UROonco24, UROonco25, UROwebinar, Webinar, zero-ischaemia surgery
Show all

Durvalumab monotherapy versus active monitoring for resected primary renal cell carcinoma in RAMPART: An international, phase 3, randomized controlled trial

ASCO2026

ctDNA analysis in participants with renal cell carcinoma treated with adjuvant pembrolizumab or placebo in the KEYNOTE-564 trial

ASCO2026

KIM-1 in advanced papillary and clear cell renal cell carcinoma

European Urology, April 2026

Development and internal validation of a novel prognostic score for real-world renal cell carcinoma patients eligible for adjuvant therapy

AUA26, May 2026

Association of serum Kidney Injury Molecule (KIM-1) with treatment response and survival in metastatic kidney cancer

AUA26, May 2026

Comparison between IO-IO and IO-TKI combination therapies for renal cell carcinoma with inferior vena cava thrombus

AUA26, May 2026

Cambridge kidney One-Stop Mass Investigation Clinic (CkOSMIC): A nonrandomised feasibility study

European Urology Oncology, February 2026

Radiomics and image-based artificial intelligence for predicting recurrence and survival after surgery in localised renal cell carcinoma: An APPRAISE-AI systematic review and meta-analysis

European Urology Focus, January 2026

Comparison of patients with and without tumor pseudocapsule rupture during robot-assisted partial nephrectomy at a high-volume tertiary care referral center

Kidney-sparing treatments for local recurrence in renal cell tumours after partial nephrectomy or focal therapy: A systematic review

European Urology Focus, December 2025

MLH1 mismatch repair deficiency predicts exceptional response to immune checkpoint inhibition in clear-cell renal cell carcinoma

European Urology, November 2025

LenCabo: A randomized phase II multicenter trial of lenvatinib plus everolimus (len/eve) versus (vs) cabozantinib (cabo) in patients (pts) with metastatic clear cell RCC (ccRCC) that progressed on PD-1 immune checkpoint inhibition (ICI)

ESMO25, October 2025

PreviousNext